[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609576":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":21,"responsibleParty":62,"collaborators":7,"id":64,"slug":7,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":7,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":7,"targetDuration":7,"studyType":73,"phases":7,"briefSummary":74,"conditions":75,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"KalVista Pharmaceuticals, Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Sebetralstat","Oral Plasma Kallikrein Inhibator",[14],"KVD900",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"KalVista Pharmaceuticals Ltd","CONTACT","1 (857) 999-0075","expandedaccess@kalvista.com",[22,35,44,53],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":7},"KalVista Investigative Site","AVAILABLE","Evansville","Indiana","47715","United States",{"type":30,"coordinates":31},"Point",[32,33],-87.55585,37.97476,{"lat":33,"lon":32},{"facility":23,"status":24,"city":36,"state":37,"zip":38,"country":28,"cosmosGeoPoint":39,"geoPoint":43,"contacts":7},"Wheaton","Maryland","20902",{"type":30,"coordinates":40},[41,42],-77.05526,39.03983,{"lat":42,"lon":41},{"facility":23,"status":24,"city":45,"state":46,"zip":47,"country":28,"cosmosGeoPoint":48,"geoPoint":52,"contacts":7},"St Louis","Missouri","63110",{"type":30,"coordinates":49},[50,51],-90.19789,38.62727,{"lat":51,"lon":50},{"facility":23,"status":24,"city":54,"state":55,"zip":56,"country":28,"cosmosGeoPoint":57,"geoPoint":61,"contacts":7},"San Antonio","Texas","78229",{"type":30,"coordinates":58},[59,60],-98.49363,29.42412,{"lat":60,"lon":59},{"type":63,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100609576",false,"NCT07216378","Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat","On Demand Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With Hereditary Angioedema (HAE) With Sebetralstat","Inclusion Criteria:\n\n* Male or female patients 2 to 11 years of age.\n* Parent or LAR provides signed informed consent and patient provides assent (when applicable).\n* Confirmed diagnosis of HAE.\n\nExclusion Criteria:\n\n* Confirmed diagnosis of HAE with nC1-INH or acquired angioedema\n* Patient weighs \\\u003C9.5 kg\n* Patient participated in the KVD900-303 trial and withdrew prior to trial completion per the protocol or trial closure\n* Any clinically significant medical condition or medical history that, in the opinion of the Treating Physician, would interfere with the patient's safety.\n* Known hypersensitivity to sebetralstat or its excipients.\n* Patient with a medical history or known to have severe hepatic impairment (Child Pugh C).\n* Patients who require sustained use of strong cytochrome P450 3A4 inhibitors or inducers.","ALL","2 Years","11 Years","EXPANDED_ACCESS","The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Hereditary Angioedema (HAE) pediatric (ages 2-11) post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.",[76],"Hereditary Angioedema","2026-05-27",{"date":79,"type":80},"2026-05-28","ACTUAL",{"name":5,"class":6},4]